TRIAL DETAIL
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (Japan)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (Japan) |
|||
NCT#: |
||||
Conditions: |
Advanced Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 11/01/2005 |
Age of Trial (yrs) 19.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor
VEGFR inhibitor (TKI) |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
20050129 |
|||
Sponsor: |
Amgen Inc. |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
PURPOSE: Motesanib (AMG 706) is a multitargeted anticancer agent with an inhibitory action on the human vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and the cellular stem-cell factor receptor (KIT). The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |